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ABSTRACT 
Vibrio vulnificus is an opportunistic human pathogen causing septicemia, and the infection is 
characterized by formation of the edematous skin lesions on limbs. This pathogenic species 
secretes a thermolysin-like metalloprotease as a virulence determinant. The metalloprotease 
was confirmed to activate human factor XII-plasma kallikrein-kinin cascade that results in 
liberation of bradykinin, a chemical mediator enhancing the vascular permeability, from 
high-molecular weight kininogen. Namely, the metalloprotease showed to generate active 
fragments by cleavage of Arg-Ile, Arg-Val or Gly-Leu peptide bond in human zymogens 
(plasma prekallikrein and factor XII). In spite of induction of the sufficient vascular 
permeability-enhancing and edema-forming reaction in the guinea pig model, a serine 
protease from V. parahaemolyticus, a human pathogen causing primarily watery diarrhea, 
showed far less ability to activate and to cleave the human zymogens. These results in part 
may explain why only V. vulnificus often causes serious edematous skin damages in humans. 
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INTRODUCTION 
Vibrio vulnificus, an opportunistic human pathogen, causes fatal septicemia characterized by 
formation of the edematous skin lesions on limbs (Janda et al., 1988; Park et al., 1991). This 
human pathogen secretes a zinc metalloprotease of the thermolysin family (Hooper, 1994; 
Miyoshi and Shinoda, 2000) as an important virulence determinant (Miyoshi and Shinoda, 
1993). For instance, when injected into the dorsal skin of a guinea pig, V. vulnificus 
metalloprotease enhances vascular permeability through activation of the factor XII-plasma 
kallikrein-kinin cascade that results in liberation of bradykinin, an inflammatory mediator, 
from high-molecular-weight kininogen (Miyoshi et al., 1987; Molla et al., 1989). This vibrio 
metalloprotease may also activate the human cascade because the in vitro study using purified 
human proteins indicated conversion of both factor XII and plasma prekallikrein to active 
forms (Miyoshi and Shinoda, 1992). However, the mechanism by which V. vulnificus 
metalloprotease can convert human zymogens is not clarified yet. Some other human 
pathogenic Vibrio species including V. parahaemolyticus, an etiologic agent causing watery 
diarrhea, secretes serine proteases (Ishihara et al., 2002; Lee et al., 2002). Although this serine 
protease can digest various host proteins, its biological or pathogenic actions are not 
documented.  
Herein, we report that V. vulnificus metalloprotease can generate active fragments from 
human zymogens, factor XII and plasma prekallikrein, through cleavage of Arg-Ile, Arg-Val 
or Gly-Leu peptide bond, whereas V. parahaemolyticus serine protease has far less activity to 
generate active human fragments in spite of the enough potential to activate the guinea pig 
factor XII-plasma kallikrein-kinin cascade. 
 
MATERIALS AND METHODS 
Substances 
 4
Bovine serum albumin, teprotide, soybean trypsin inhibitor and hexadimethrine bromide were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Carbobenzoxy-Phe-Arg-4-methyl-coumaryl-7-amide (Z-Phe-Arg-MCA) and 
t-butyloxycarbonyl-Gln-Gly-Arg-MCA (Boc-Gln-Gly-Arg-MCA) were from Peptide Institute 
(Minoh, Osaka, Japan). Purified human plasma prekallikrein and factor XII were purchased 
from Enzyme Research Laboratories Inc. (South Bend, IN, USA), and human plasma was 
from George-King Bio-Medical Inc. (Overland Park, KS, USA). 
 
Preparations of vibrio proteases 
The recombinant V. vulnificus metalloprotease (45-kDa) was isolated from the periplasmic 
fraction of a transformant by ammonium sulfate precipitation followed by column 
chromatography on a HiLoad 16/10 Phenyl Sepharose column (Amersham Biosciences, 
Piscataway, NJ, USA) as described (Miyoshi et al., 1997). V. parahaemolyticus serine 
protease (50-kDa) was purified according to the procedures reported by Ishihara et al. (2002). 
Namely, it was purified from the culture supernatant of a clinical strain by ammonium sulfate 
fractionation, gel filtration on a HiLoad 26/60 Sephacryl S-200 HR column, and ion-exchange 
chromatography on a Fractogel TMAE-650 10/2 column. Both proteases thus obtained 
revealed a single protein band in SDS-PAGE. 
 
Permeability-enhancing activity 
The vascular permeability-enhancing activity was measured as described (Miyoshi et al., 
1987). The protease sample diluted with 0.9 % NaCl were injected into the dorsal skin of a 
male Hartley guinea pig (300-400 g), which was previously injected intravenously with 5 % 
Evans blue (1.0 ml/kg of body weight). At 30-min postinjection, the dorsal skin was flayed, 
and the area of the blueing spot was measured. In order to test effect of teprotide or soybean 
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trypsin inhibitor, each substance (5 nmol) was mixed with the sample and administrated 
intradermally. The animals used were anesthetized with sodium pentobarbital (20 mg/kg of 
body weight). 
 
Generation of plasma kallikrein in mammalian plasma 
In order to remove α-macroglobulin (α M), a broad-spectrum protease inhibitor in 
mammalian plasma (Sottrup-Jensen, 1989), human or guinea pig plasma was pretreated with 
the IgG antibody against each α M at 4 oC for 20 min. Thereafter, the antibody-treated plasma 
was diluted to 10-fold with the assay buffer (50 mM Tris-HCl buffer supplemented with 
0.9 % NaCl, 0.02 % NaN3, 0.01 % bovine serum albumin and 0.05 % hexadimethrine 
bromide; pH 8.0). This diluted plasma (0.5 ml) was incubated with an appropriate amount of 
the sample at 30 oC in the presence of 0.2 mM Z-Phe-Arg-MCA, and the increase of 
absorbance at 370 nm due to liberation of 7-amino-4-metylcoumarin (AMC) from the 
substrate was measured periodically. Thereafter, the amount of AMC liberated was calculated. 
The experiments were repeated two or three times; however, only the representative 
results from one series of experiments were shown in "RESULTS". 
 
Activation of human zymogens 
To test activation by V. vulnificus metalloprotease, purified human plasma prekallikrein (36 
nM) or factor XII (68 nM), of which concentration is about one-fifth in human plasma, was 
mixed with the metalloprotease (10 nM) and the suitable substrate (0.2 mM) in a total of 0.5 
ml of the assay buffer. The reaction mixture was incubated at 30 oC, the increase of 
absorbance at 370 nm was measured periodically, and the amount of AMC liberated was 
calculated. In case of V. parahaemoyticus serine protease, the serine protease (50 nM) was 
allowed to act on plasma prekallikrein (36 nM) in the presence or absence of factor XII (68 
 6
nM). 
The experiments were repeated two or three times; however, only the representative 
results from one series of experiments were shown in "RESULTS". 
 
Fragmentation of human zymogens 
In the absence of bovine serum albumin, V. vulnificus metalloprotease (0.1 μM) was allowed 
to act on plasma prekallikrein (1.4 μM) or factor XII (2.5 μM) at 30 oC for 1 min. In case of V. 
parahaemoyticus serine protease, the serine protease (0.8 μM) was allowed to act on human 
factor XII (3.0 μM) for 1 or 5 min. Thereafter, the reaction was terminated by the addition of 
an equal volume of 10 % trichloroacetic acid. The precipitate was rinsed two times with 
100 % ethanol and mixed with 0.5 M Tris-HCl containing 2 % SDS, 5 % 2-mercaptoethanol, 
0.05 % bromophenol blue and 70 % glycerol (pH 6.8). The sample thus prepared was treated 
at 100 oC for 5 min for SDS-PAGE. SDS-PAGE using a Phast System (Amersham 
Biosciences) was carried out with a PhastGelTM Gradient 10-15 Gel according to the 
instructions provided by the manufacturer. 
 
Determination of N-terminal amino acid sequences 
The proteins separated by SDS-PAGE were transferred to a PVDF membrane using a Phast 
System and stained with Coomassie brilliant blue. Thereafter, the membrane was rinsed 
several times with distilled water, and each protein band was cut off. The N-terminal amino 
acid sequence was determined by automated Edman degradation with a Model 491 protein 
sequencer (Applied Biosystems, Foster City, CA, USA) equipped with an online Model 120A 
PTH-amino acid analyzer. 
 
RESULTS AND DISCUSSION 
 7
Activation and fragmentation of human zymogens by V. vulnificus metalloprotease 
The recombinant V. vulnificus metalloprotease was used in the present experiments because of 
convenience of its purification (Miyoshi et al., 1997). The metalloprotease gene transformed 
into Escherichia coli is expressed by its own promoter, and the enzyme precursor produced is 
processed normally through autocatalytic removal of the N-terminal propeptide. Therefore, 
the recombinant enzyme has an equal proteolytic activity to the native enzyme isolated from 
the culture supernatant of the vibrio. In order to reconfirm the correct maturation of the 
recombinant V. vulnificus metalloprotease, it was allowed to act on human plasma 
prekallikren or factor XII in the presence of the suitable substrate, Z-Phe-Arg-MCA (for 
plasma kallikrein) or Boc-Gln-Gly-Arg-MCA (for activated factor XII). Although the 
recombinant enzyme itself showed no amidolytic activity, steady generation of the amidolytic 
activity toward each of the substrates was observed in a time-dependent manner (Fig. 1A), 
indicating activation of either human zymogens by the recombinant enzyme which was 
maturated correctly. 
Various endogenous serine proteases have been documented to achieve activation of the 
human zymogens through digestion of the N-terminal polypeptides, which results in 
generation of the active C-terminal fragments (Tanaka et al., 1992; Hovinga et al., 1994). V. 
vulnificus metalloprotease was tested to see if it also causes fragmentation of the human 
zymogens. When incubated at 30 oC for 1 min, the metalloprotease could generate the 36-kDa 
fragment from plasma prekallikrein (Fig. 2A). Analysis of the N-terminal amino acid 
sequence of the fragment revealed that V. vulnificus metalloprotease cleaved Arg371-Ile372 
peptide bond, of which the cleavage site is identical with those of endogenous serine 
proteases including activated factor XII (Tanaka et al., 1992). Likewise, the 30-kDa fragment 
was generated via cleavage of the peptide bond, Arg353-Val354 or Gly357-Leu358, when factor 
XII was incubated with the metalloprotease for 1 min (Fig. 2A). It should be noted that one of 
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these cleavage sites is identical with that of plasma kallikrein (Hovinga et al., 1994).  
Fig. 3 shows the proposed mechanism in the activation of the human factor XII-plasma 
kallikrein-kinin cascade by V. vulnificus metalloprotease. The human cascade may be 
activated via generation of active C-terminal fragments through hydrolysis of the amino 
group side of hydrophobic amino acid residues.  
On the studies using synthetic oligopeptide substrates, as well as other bacterial 
metalloproteases of the thermolysin family (Morihara and Tsuzuki, 1971), V. vulnificus 
metalloprotease have been believed to hydrolyze specifically the peptide bond at the amino 
group side of the P1’ amino acid residue, usually a hydrophobic amino acid residue (Miyoshi 
and Shinoda, 2000). The results shown in the present study using the native protein substrates 
are apparently consistent with this conclusion. Namely, V. vulnificus metalloprotease was 
found to cleave Arg-Ile/Val or Gly-Leu peptide bond of human plasma prekallikrein or factor 
XII. 
 
Activation and fragmentation of human zymogens by V. parahaemolyticus serine protease 
The serine protease from V. parahaemolyticus, a human pathogen causing gastrointestinal 
diseases, was also found to evoke enough permeability-enhancing reaction in the in vivo 
guinea pig model (data not shown). As well as that by V. vulnificus metalloprotease (Miyoshi 
et al., 1987), the permeability enhancement caused by the serine protease was augmented 
about 3-fold by simultaneous administration of teprotide, a kininase inhibitor, whereas 
inhibited almost completely by soybean trypsin inhibitor, a well-known inhibitor of plasma 
kallikrein (data not shown). Since each inhibitor showed no effect on the proteolytic activity, 
it might be concluded that V. parahaemolyticus serine protease also enhanced vascular 
permeability through activation of the factor XII-plasma kallikrein-kinin cascade.  
To verify activation of the guinea pig cascade, the serine protease was allowed to act on 
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guinea pig plasma, and generation of plasma kallikrein was traced periodically by measuring 
liberation of AMC from the substrate. As well as V. vulnificus metalloprotease (Miyoshi and 
Shinoda, 1992; Miyoshi et al., 1994), V. parahaemolyticus serine protease could not generate 
significant amounts of plasma kallikrein because of quickly inactivation by α M (data not 
shown). However, as shown in Fig. 4, the serine protease could elicit time-dependent 
generation of plasma kallikrein after a short lag period when allowed to act on α M-free 
plasma. In case of α M-free human plasma, whereas, far less generation of plasma kallikrein 
was observed after as long as an 8-min lag period (Fig. 4). It should be emphasized that, in 
both cases, V. vulnificus metalloprotease showed much more efficient generation of plasma 
kallikrein without the lag period (Fig. 4). These findings suggest indirect generation of 
kallikrein by V. parahaemolyticus serine protease. In order to study the indirect kallikrein 
generation, the serine protease was allowed to act on purified human plasma prekallikrein in 
the presence or absence of factor XII. Only in the presence of factor XII, generation of plasma 
kallikrein was observed after an 8-min lag period (Fig. 1B) indicating that V. 
parahaemolyticus serine protease may slowly generate the active fragment from human factor 
XII, which in turn converts plasma prekallikrein to kallikrein.  
As shown in Fig. 2B, V. parahaemolyticus serine protease also generated the 30-kDa 
fragment from factor XII when the mixture of the concentrated proteins were allowed to 
incubate at 30 oC. The analysis of the N-terminal amino acid sequence of the fragment 
revealed that the Thr352-Arg353 peptide bond was cleaved by the serine protease. This cleavage 
site is only 1 residue toward the N-terminal from that of V. vulnificus metalloprotease. Taken 
together, although V. parahaemolyticus serine protease is also a potent activator of the human 
factor XII-plasma kallikrein-kinin cascade, its action is operated after a long lag-period, and 
its potential is far less than V. vulnificus metalloprotease.  
In spite of the powerful ability to generate plasma kallikrein in vitro (Fig. 4), in guinea 
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pig model, V. vulnificus metalloprotease elicited slightly weaker permeability-enhancing 
reaction in vivo (data not shown). Thermolysin and related metalloproteases have been 
documented to have the kininase activity causing digestion of bradykinin (Zevaco and 
Desmazeaud, 1980; Wolz and Bond, 1990; Carvalho et al., 1992). Therefore, due to its own 
kininase activity, V. vulnificus metalloprotease may attenuate the vascular 
permeability-enhancing reaction evoked by bradykinin generated in situ. In deed, when V. 
vulnificus metalloprotease was allowed to act on bradykinin, the steady hydrolysis and 
inactivation of bradykinin was observed in a dose-dependent manner. Additionally, 
carboxypeptidase B, a kininase-like pancreatic enzyme known to reduce the 
permeability-enhancing reaction induced by guinea pig plasma kallikrein (Imamura et al., 
1984), showed negligible effect on the permeability enhancement elicited by V. vulnificus 
metalloprotease. 
Production of the metalloprotease by V. vulnificus is positively regulated by the 
quorum-sensing or cell density-dependent system, in which a small extracellular substance 
called the autoinducer operates as a bacterial pheromone (Kim et al., 2003). Namely, 
expression of the metalloprotease gene is augmented at stationary growth phase because of 
sufficient bacterial multiplication followed by accumulation of the autoinducer. Watanabe et 
al. (2004) recently reported that V. vulnificus has prominent potentials to grow and to produce 
the metalloprotease in human serum, which are thought to be a crucial cause of serious 
systemic diseases by this species. In addition to them, the present study evidently showed that 
V. vulnificus metalloprotease had sufficient ability to activate the human 
bradykinin-generating cascade. This finding may explain, at least partially, why only V. 
vulnificus often causes fatal infections in humans. 
The guinea pig model has been used for evaluation of abilities of various microbial 
proteases to activate the factor XII-plasma kallikrein-kinin cascade (Molla et al., 1989; 
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Kaminishi et al., 1990; Maruo et al., 1993). However, the present data demonstrated that this 
model might sometimes cause overestimation of the pathological ability of the protease tested. 
On guinea pig factor XII and plasma prekallikrein, the amino acid sequences around the 
cleavage sites are different from those of human zymogens (Semba et al., 1993; Shibuya et al., 
1999). These replacements of amino acids may cause significant increase in activation 
efficiency of the guinea pig zymogens by microbial proteases. Therefore, as suggested by 
Shibuya et al. (1999), the ability to hydrolyze the synthetic peptides mimicking the cleavage 
sites of human zymogens may be more credible to evaluate the pathological potentials of the 
proteases. 
In summary, even though it does not show the excellent activity in guinea pig models, V. 
vulnificus metalloprotease may be a suitable enzyme to activate the bradykinin-generating 
cascade in humans. 
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FIGURE LEGENDS 
Fig. 1. Activation of human zymogens by vibrio proteases. (A) V. vulnificus metalloprotease 
(10 nM) was mixed with plasma prekallikrein (36 nM) and Z-Phe-Arg-MCA (0.2 mM), or 
factor XII (68 nM) and Boc-Gln-Gly-Arg-MCA (0.2 mM) in a total of 0.5 ml of the assay 
buffer. The reaction mixture was incubated at 30 oC, and liberation of AMC from the substrate 
was measured periodically. (B) V. parahaemolyticus serine protease (50 nM) was allowed to 
act on plasma prekallikrein (36 nM) in the presence or absence of factor XII (68 nM) at 30 oC, 
and liberation of AMC from Z-Phe-Arg-MCA was measured periodically.  
 
Fig. 2. Fragmentation of human zymogens by vibrio proteases. (A) Human plasma 
prekallikrein (1.4 μM) or factor XII (2.5 μM) was mixed with the assay buffer (-) or 0.1 μM 
of V. vulnificus metalloprotease (+). Thereafter, the reaction mixture was incubated at 30 oC 
for 1 min, and subjected to SDS-PAGE using a PhastGelTM Gradient 10-15 Gel. (B) Human 
factor XII (3.0 μM) was mixed with the assay buffer (-) or 0.8 μM of V. parahaemolyticus 
serine protease (+). Each mixture was incubated at 30 oC for 1 or 5 min, and subjected to 
SDS-PAGE using a PhastGelTM Gradient 10-15 Gel. 
 
Fig. 3. Schematic representation of activation mechanism of the human factor XII-plasma 
kallikrein-kinin cascade by V. vulnificus metalloprotease. 
 
Fig. 4. Generation of plasma kallikrein in α M-free mammalian plasma by vibrio proteases. 
At 30 oC, V. vulnificus metalloprotease (20 nM) or V. parahaemolyticus serine protease (50 
nM) was allowed to act on 0.5 ml of the 10-fold diluted guinea pig or human plasma 
pretreated with the antibody against α M, and liberation of AMC from Z-Phe-Arg-MCA was 
measured periodically.  
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